Yahoo · Sep 18, 2026
BMY vs. ARGX: Which Stock Is the Better Value Option?
BMY vs. ARGX: Which Stock Is the Better Value Option?
AR
NYSE · ARGX
argenx SE
Healthcare · Biotechnology
$990.32
Down-$5.45 (-0.55%)
Updated Sep 20, 2026, 11:41 AM
SID Score
6.1/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 47.46B
- P/E ratio
- 42.26
- Dividend yield
- 0.00%
- 52-week range
- $661.85 – $1,072.75
- Volume
- 244.02K
- Avg. volume
- 347.54K
Price performance
ARGX price history
1M range · 19 trading sessions · Daily adjusted prices
ARGX closed at $990.32 after 19 trading sessions, down 2.06% for the selected period.
- Last close
- $990.32
- Period change
- -2.06%
- Period low
- $979.76
- Period high
- $1,058.90
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $1,001.62 | $1,003.83 | $989.33 | $990.32 | 244.02K |
| Sep 17, 2026 | $991.74 | $1,000.87 | $988.565 | $995.77 | 245.9K |
| Sep 16, 2026 | $981.94 | $988.335 | $974.26 | $984.69 | 200.56K |
| Sep 15, 2026 | $985.87 | $1,000.59 | $977.03 | $979.76 | 235.3K |
| Sep 14, 2026 | $1,004.56 | $1,008.32 | $988.40 | $990.54 | 198.6K |
| Sep 11, 2026 | $1,001.62 | $1,002.95 | $983.10 | $984.39 | 181.88K |
| Sep 10, 2026 | $991.05 | $1,000.24 | $981.74 | $984.04 | 226.47K |
| Sep 9, 2026 | $991.68 | $1,008.93 | $988.69 | $1,002.31 | 209.93K |
| Sep 8, 2026 | $1,005.68 | $1,015.79 | $995.00 | $1,007.07 | 313.88K |
| Sep 4, 2026 | $1,040.31 | $1,048.435 | $1,031.19 | $1,033.15 | 125.06K |
| Sep 3, 2026 | $1,070.81 | $1,070.81 | $1,052.78 | $1,053.46 | 210.44K |
| Sep 2, 2026 | $1,049.46 | $1,072.75 | $1,042.22 | $1,055.37 | 216.99K |
| Sep 1, 2026 | $1,033.36 | $1,039.13 | $1,021.5501 | $1,028.51 | 192.94K |
| Aug 31, 2026 | $1,010.78 | $1,039.36 | $1,005.78 | $1,031.66 | 227.99K |
| Aug 28, 2026 | $1,049.87 | $1,053.00 | $1,018.60 | $1,023.21 | 175.52K |
| Aug 27, 2026 | $1,053.47 | $1,061.57 | $1,044.76 | $1,058.90 | 322.52K |
| Aug 26, 2026 | $1,033.83 | $1,057.91 | $1,032.85 | $1,047.10 | 362.1K |
| Aug 25, 2026 | $1,020.29 | $1,030.3599 | $1,013.75 | $1,019.49 | 142.23K |
| Aug 24, 2026 | $1,023.76 | $1,031.18 | $1,001.505 | $1,011.11 | 318.43K |
Latest ARGX news
The latest Smart Investors Daily articles mentioning ARGX.
Stock researchCompany · Overview
ARGX research
Overview
Company profile and research snapshot.
Company profile
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $967.36
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 12, 2026 | TD COWEN | Buy | — |
| Jul 12, 2026 | DAY BY DAY | Buy | — |
| Jul 1, 2026 | KBC SECURITIES | Buy | — |
| Jun 24, 2026 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
News briefing
Generated Sep 20, 2026, 11:05 AM
Why Is ARGX Down Today?
argenx SE (ARGX) is trading down $5.45 (0.55%) today amid relatively modest corporate news and ongoing valuation comparisons within the biotech sector. The decline appears driven by broader market sentiment rather than company-specific negative developments, with shareholder governance updates and competitive positioning taking center stage.
Bottom line: argenx is experiencing a modest decline today as corporate governance news fails to offset broader biotech sector headwinds and investor focus on clinical/commercial milestones. The stock's near-term trajectory will largely depend on upcoming pipeline catalysts and clinical trial data, while the new board appointments position the company for strategic decision-making. Investors should monitor upcoming clinical readouts and any partnership or licensing announcements as key inflection points for valuation re-rating.
Yahoo · Sep 17, 2026
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors. “We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. Our focus at argenx today remains as
ChartMill · Sep 17, 2026
ARGENX SE - ADR (NASDAQ:ARGX) Meets Minervini Trend Template and High Growth Momentum
ARGX passes Minervini’s Trend Template plus High Growth Momentum, with strong EPS/revenue growth, high relative strength, and a Stage 2 uptrend.
SeekingAlpha · Sep 14, 2026
argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
argenx SE (ARGX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 9:15 AM EDTCompany ParticipantsKarl Gubitz - Chief Financial...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
